ATCC

PRODUCT SPOTLIGHT



ORGANOIDS

PATIENT-DERIVED CANCER MODELS

As part of our pledge to elevate biological models, ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation organoids. ATCC is committed to making available a growing collection of models generated by the HCMI, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These HCMI models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.

To enhance their clinical relevance, the sequence data and patient clinical information for each model is available to the research community.

- All models are human patient-derived
- Diverse genetic backgrounds
- Clinical and sequencing data available via the HCMI portal
- Models from primary, metastatic, and recurrent cancer
- Rare and pediatric cancers included
- Model-specific, easy-to-follow culturing protocols

Patient-derived cancer models of the following physiological systems will be available:

- Circulatory System
- Digestive System
- Excretory System
- Integumentary System
- Musculo-skeletal System
- Nervous System
- Reproductive System
- Respiratory System

WWW.ATCC.ORG/ORGANOIDS

NEXT-GENERATION CANCER MODELS

ORGANOIDS



Organoids are complex, self-organizing microtissues grown embedded within 3-D extracellular matrix. Primary patient-derived organoids have been described for various tissues, healthy and cancerous, including colon, intestine, stomach, breast, esophagus, lung, liver, prostate, and pancreas. Organoids are invaluable pre-clinical models for studying cancer and offer many advantages over existing human or non-human animal cancer models.

- May contain multiple differentiated cell types
- Exhibit cellular polarization
- Often possess a central lumen or other in vivo–like architecture
- Can remain phenotypically and genotypically stable after long term expansion

ABOUT HUMAN CANCER MODELS INITIATIVE (HCMI)



HCMI is an international consortium that is dedicated to generating novel human tumor-derived culture models with associated genomic and clinical data. The HCMI consortium comprises funding agencies and cancer model development institutions. The consortium's funding agencies include:

- National Cancer Institute (NCI)
- Cancer Research UK (CRUK)
- Hubrecht Organoid Technology (HUB)
- Wellcome Sanger Institute (WSI)

NCI-funded model development institutions include the Broad Institute and the Cold Spring Harbor Laboratory. CRUK and WSI co-fund organoid development in the United Kingdom; CRUK provides the patient samples, while WSI derives and sequences the organoid models. The foundation HUB is a Netherlands-based not-for-profit organization that derives and sequences organoid models. ATCC was selected as the sole distributor for the HCMI models. At ATCC the models are authenticated, expanded, preserved, and made available for global distribution. The HCMI model data is provided as an open source to the research community.

Tissue of Origin	Disease	ATCC® No.
Ampulla Of Vater	Carcinoma	PDM-218™, PDM-102™
Ampulla Of Vater; Metastatic Site: Lymph Node	Cancer	PDM-369™, PDM-445™
Breast	Cancer	PDM-92™, PDM-195™, PDM-250™, PDM-350™, PDM-520™
Breast; Metastatic Site: Abdomen	Cancer	PDM-523™
Breast; Metastatic Site: Lymph Node	Cancer	PDM-411™
Colon	Adenocarcinoma	PDM-1™, PDM-45™, PDM-46™, PDM-50™, PDM-51™, PDM-52™, PDM-53™, PDM-54™, PDM-56™, PDM-57™, PDM-58™, PDM-59™, PDM-60™, PDM-61™, PDM-64™, PDM-94™, PDM-95™, PDM-98™, PDM-183™, PDM-184™, PDM-185™, PDM-186™, PDM-188™, PDM-189™, PDM-256™, PDM-260™, PDM-261™, PDM-262™, PDM-265™, PDM-266™
Colon	Cancer	PDM-99™, PDM-187™, PDM-247™ PDM-255™, PDM-354™, PDM-356™, PDM-357™, PDM-359™, PDM-363™, PDM-364™, PDM-375™, PDM-408™, PDM-416™, PDM-420™, PDM-422™, PDM-513™, PDM-539™
Colon	Adenoma	PDM-48™, PDM-274™, PDM-276™
Colon; Metastatic Site: Colon	Adenocarcinoma	PDM-427™
Colon; Metastatic Site: Liver	Adenocarcinoma	PDM-42™
Colon; Metastatic Site: Liver	Cancer	PDM-372™, PDM-410™, PDM-418™, PDM-425™, PDM-426™, PDM-537™
Colon; Metastatic Site: Lymph Node	Cancer	PDM-275™, PDM-277™
Colon; Metastatic Site: Pelvis	Cancer	PDM-417™
Colon; Metastatic Site: Peritoneum	Cancer	PDM-415™
Esophagus	Adenocarcinoma	PDM-68™, PDM-69™, PDM-70™, PDM-71™, PDM-72™, PDM-74™, PDM-75™, PDM-76™, PDM-77™, PDM-78™, PDM-79™, PDM-80™, PDM-81™, PDM-82™, PDM-84™, PDM-85™, PDM-86™, PDM-87™, PDM-88™, PDM-89™, PDM-120™, PDM-124™, PDM-131™, PDM-159™
Esophagus	Cancer	PDM-65™, PDM-67™, PDM-73™, PDM-225™, PDM-339™, PDM-469™, PDM-512™
Esophagus	Malignant neoplasm	PDM-83™
Esophagus; Metastatic Site: Abdominal Cavity	Cancer	PDM-470™
Esophagus; Metastatic Site: Liver	Adenocarcinoma	PDM-119™
Esophagus; Metastatic Site: Liver	Cancer	PDM-468™
Esophagus; Metastatic Site: Peritoneum	Adenocarcinoma	PDM-158™
Esophagus; Metastatic Site: Peritoneum	Cancer	PDM-488™
Esophagus; Metastatic Site: Pleura	Cancer	PDM-243™
Esophagus; Metastatic Site: Stomach	Cancer	PDM-490™
Extrahepatic Bile Duct	Adenocarcinoma	PDM-216™, PDM-217™, PDM-220™
Gall bladder: IPMN	Benign neoplasm premalignant	PDM-273™
Liver	Cholangiocarcinoma	PDM-219™
Lung	Adenocarcinoma	PDM-3™
Lung	Cancer	PDM-683™, PDM-685™
Neck	Cancer	PDM-428™, PDM-431™, PDM-440™, PDM-441™
Ovary	Cancer	PDM-514™, PDM-515™
Pancreas	Adenocarcinoma	PDM-24™, PDM-25™, PDM-26™, PDM-27™, PDM-28™, PDM-29™, PDM-30™, PDM-31™, PDM-32™, PDM-33™, PDM-34™, PDM-35™, PDM-36™, PDM-37™, PDM-38™, PDM-39™, PDM-40™, PDM-41™, PDM-90™, PDM-101™, PDM-108™, PDM-110™, PDM-126™, PDM-134™, PDM-137™, PDM-138™, PDM-166™, PDM-167™, PDM-168™, PDM-173™, PDM-197™, PDM-200™, PDM-201™, PDM-204™, PDM-221™, PDM-222™
Pancreas	Cancer	PDM-203™, PDM-205™, PDM-270™, PDM-421™, PDM-423™
Pancreas	Cyst	PDM-573™

Tissue of Origin	Disease	ATCC® No.
Pancreas; Metastatic Site: Abdomen	Adenocarcinoma	PDM-169™
Pancreas; Metastatic Site: Liver	Adenocarcinoma	PDM-106™, PDM-289™
Pancreas; Metastatic Site: Liver	Cancer	PDM-288™
Pancreas; Metastatic Site: Liver	Malignant neoplasm	PDM-179™
Pancreas; Metastatic Site: Lymph Node	Cancer	PDM-223™
Pancreas; Metastatic Site: Peritoneum	Adenocarcinoma	PDM-164™
Pancreas; Metastatic Site: Pleural Cavity	Adenocarcinoma	PDM-165™, PDM-170™, PDM-171™
Rectosigmoid Junction	Adenocarcinoma	PDM-6™, PDM-100™, PDM-264™
Rectum	Adenocarcinoma	PDM-43™, PDM-47™, PDM-49™, PDM-55™, PDM-62™, PDM-63™, PDM-96™, PDM-97™, PDM-190™, PDM-191™
Rectum	Adenoma	PDM-44™, PDM-279™
Rectum	Cancer	PDM-254™, PDM-257™, PDM-258™, PDM-263™, PDM-330™, PDM-331™, PDM-414™
Rectum; Metastatic Site: Liver	Adenocarcinoma	PDM-9™, PDM-103™, PDM-419™
Sigmoid Colon	Adenocarcinoma	PDM-2™, PDM-4™, PDM-5™, PDM-7™, PDM-8™
Small Intestine	Adenoma	PDM-368™
Small Intestine	Cancer	PDM-272™
Small Intestine; Metastatic Site: Lymph Node	Cancer	PDM-373™, PDM-374™
Stomach	Adenocarcinoma	PDM-136™, PDM-146™
Stomach	Cancer	PDM-233™, PDM-226™, PDM-296™, PDM-308™, PDM-376™, PDM-377™, PDM-519™
Stomach; Metastatic Site: Ascites	Adenocarcinoma	PDM-162™
Stomach; Metastatic Site: Ascites	Cancer	PDM-315™, PDM-316™, PDM-323™, PDM-489™
Stomach; Metastatic Site: Lymph Node	Adenocarcinoma	PDM-135™
Stomach; Metastatic Site: Pleural Cavity	Cancer	PDM-161™
Stomach; Metastatic Site: Pleural Cavity	Adenocarcinoma	PDM-116™
Uterus; Endometrium	Cancer	PDM-527™, PDM-528™, PDM-587™, PDM-589™, PDM-590™, PDM-603™

10801 University Boulevard
Manassas, Virginia 20110-2209

703.365.2700 703.365.2701 sales@atcc.org www.atcc.org

Organ-082026-v04